Skip To Main Content
Francesca Bruce on Muck Rack

Francesca Bruce

Verified
As seen in: Scrip, The Pink Sheet, Generics Bulletin, HBW Insight, In Vivo, Citeline, Medtech Insight
I am a senior writer at the Pink Sheet, all views expressed are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Francesca

Contact Francesca, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Francesca Bruce’s Biography

Read Full Bio →

Francesca covers a range of policy and regulatory developments in Europe, with a focus on pricing and reimbursement and market access. In her role at Scrip she has also covered key emerging markets in Latin America, concentrating on Brazil, Mexico and Argentina.

Articles

Could USTR German Pricing Investigation Lead To Policy Misfire And Damaged Trading Relations?

|
By Francesca Bruce Verified
| The Pink Sheet Verified
Several organizations argue that the US Trade Representative should drop its investigation into German drug pricing policies. Any action resulting from the US investigation into German drug pricing may not lead to the lower US prices. (Shutterstock) Key Takeaways Critics of the US Trade Representative’s German drug pricing policy investigation say it could damage the vital economic relationship between the two countries.
Open in Who Shared Issue with article?

What Could A US-Germany Drug Pricing Deal Look Like?

|
By Francesca Bruce Verified
| The Pink Sheet Verified
Germany’s recent mandatory rebate hikes and other cost-cutting measures for drugs come under fire, as does the wider pricing and reimbursement system, in responses to the United States Trade Representative’s investigation into Europe’s biggest pharmaceutical market.
Open in Who Shared Issue with article?

Sweden Suffers Two-Pronged Attack On Availability Of Generic And Innovative Drugs

|
By Francesca Bruce Verified
| The Pink Sheet Verified
Swedish authorities are investigating how willingness to pay and the EU urban wastewater treatment directive will impact access to medicines in Sweden. Sweden is investigating how changing its willingness to pay policy will affect access to medicines. (Shutterstock) Key Takeaways The availability of medicines in Sweden is under threat from the US most favored nation (MFN) drug pricing policy and the EU Urban Wastewater Treatment Directive (UWWTD).
Open in Who Shared Issue with article?
See all 1,035 articles